On the afternoon of November 24, Zheng Lijian, Vice Chairman of Lishui Municipal Committee of the Chinese People's Political Consultative Conference (CPPCC), led a delegation to conduct a special research visit to Zhejiang Benefit Pharmaceutical Co., Ltd. The research was accompanied by leading officials including Xiang Fangyun, Director of the Hong Kong, Macao, Taiwan, Overseas Chinese and Foreign Affairs Committee of the Municipal CPPCC, and Ye Chaomin, Deputy Director of the Population, Resources, Environment and Construction Committee of the Municipal CPPCC. Wu Lihua, Chairman of Zhejiang Benefit Pharmaceutical Co., Ltd., Wu Liwei, Executive Director, and Zhu Meipeng, Production Director, warmly received the delegation.

At the beginning of the research, Chairman Wu Lihua extended a warm welcome to Vice Chairman Zheng Lijian and his delegation, and accompanied them to the Traditional Chinese Medicine (TCM) Technology and Culture Exhibition Hall of Zhejiang Benefit Pharmaceutical Co., Ltd. Through detailed graphic materials, rich product displays and a clear development context, the research team gained a comprehensive and immersive understanding of the achievements made by Zhejiang Benefit Pharmaceutical Co., Ltd. in core business layout, core technological advantages and profound industry accumulation.

Subsequently, the company systematically elaborated on its core strategies and the planning of the Grand Health Smart Future Project to the research team. Chairman Wu Lihua stated that Zhejiang Benefit Pharmaceutical Co., Ltd. is actively adapting to the trends of the times, accurately seizing the huge opportunities brought by the "silver economy", and continuously deepening its layout in the fields of Chinese-style health products and medical aesthetics. Under the guidance of this strategy, the layout of the "Zhejiang Benefit Pharmaceutical Grand Health Smart Future Factory" project marks another major layout and strategic leap for the Benefit team in the journey of continuously deepening the grand health track.

Vice Chairman Zheng Lijian commented that the development path of Zhejiang Benefit Pharmaceutical Co., Ltd., which focuses on its core business and dares to innovate, is impressive. In particular, the advancement of the "Smart Future Factory" project fully demonstrates the enterprise's ambition and courage for the future. He pointed out that the biopharmaceutical and grand health industries are strategic emerging industries with broad prospects, and he hoped that Zhejiang Benefit Pharmaceutical Co., Ltd. could:

Seize opportunities and accelerate innovation: Take the "Smart Future Factory" as a new starting point to achieve greater breakthroughs in core technology R&D.

Strictly control quality and build brands: Always adhere to the bottom line of drug safety and create a more market-competitive brand image.

Set an example and drive cluster development: Actively play the leading role of a leading enterprise and contribute more to the construction of Lishui's grand health industry cluster.